| Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind … EJ Gane, SK Roberts, CAM Stedman, PW Angus, B Ritchie, R Elston, ... The Lancet 376 (9751), 1467-1475, 2010 | 401 | 2010 |
| Clinical pharmacokinetics of non-nucleoside reverse transcriptase inhibitors PF Smith, R DiCenzo, GD Morse Clinical pharmacokinetics 40 (12), 893-905, 2001 | 275 | 2001 |
| Phase I and II study of the safety, virologic effect, and pharmacokinetics/pharmacodynamics of single-dose 3-o-(3′, 3′-dimethylsuccinyl) betulinic acid (bevirimat) against … PF Smith, A Ogundele, A Forrest, J Wilton, K Salzwedel, J Doto, ... Antimicrobial agents and chemotherapy 51 (10), 3574-3581, 2007 | 245 | 2007 |
| Activity of oral ALS-008176 in a respiratory syncytial virus challenge study JP DeVincenzo, MW McClure, JA Symons, H Fathi, C Westland, ... New England Journal of Medicine 373 (21), 2048-2058, 2015 | 243 | 2015 |
| The influence of St. John's wort on the pharmacokinetics and protein binding of imatinib mesylate P Smith, JM Bullock, BM Booker, CE Haas, CS Berenson, WJ Jusko Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 24 (11 …, 2004 | 189 | 2004 |
| Treating mammalian bite wounds PF Smith, AM Meadowcroft, DB May Journal of clinical pharmacy and therapeutics 25 (2), 85-100, 2000 | 168* | 2000 |
| Oxaliplatin in combination with protracted-infusion fluorouracil and radiation: report of a clinical trial for patients with esophageal cancer NI Khushalani, CG Leichman, G Proulx, H Nava, L Bodnar, D Klippenstein, ... Journal of clinical oncology 20 (12), 2844-2850, 2002 | 164 | 2002 |
| Inhibition of atazanavir oral absorption by lansoprazole gastric acid suppression in healthy volunteers DL Tomilo, PF Smith, AB Ogundele, R Difrancesco, CS Berenson, ... Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 26 (3 …, 2006 | 123 | 2006 |
| Analysis of hepatitis C virus decline during treatment with the protease inhibitor danoprevir using a multiscale model L Rong, J Guedj, H Dahari, DJ Coffield Jr, M Levi, P Smith, AS Perelson PLoS computational biology 9 (3), e1002959, 2013 | 116 | 2013 |
| Interactions between buprenorphine and antiretrovirals. I. The nonnucleoside reverse-transcriptase inhibitors efavirenz and delavirdine EF McCance-Katz, DE Moody, GD Morse, G Friedland, P Pade, J Baker, ... Clinical Infectious Diseases 43 (Supplement_4), S224-S234, 2006 | 105 | 2006 |
| Interactions between buprenorphine and antiretrovirals. II. The protease inhibitors nelfinavir, lopinavir/ritonavir, and ritonavir EF McCance-Katz, DE Moody, PF Smith, GD Morse, G Friedland, P Pade, ... Clinical infectious diseases 43 (Supplement_4), S235-S246, 2006 | 97 | 2006 |
| Effect of IL28B Genotype on Early Viral Kinetics During Interferon-Free Treatment of Patients With Chronic Hepatitis C TW Chu, R Kulkarni, EJ Gane, SK Roberts, C Stedman, PW Angus, ... Gastroenterology 142 (4), 790-795, 2012 | 96 | 2012 |
| A Phase I Trial of PRN1008, A Novel Reversible Covalent Inhibitor of Bruton's Tyrosine Kinase, In Healthy Volunteers PF Smith, J Krishnarajah, PA Nunn, RJ Hill, D Karr, D Tam, ... British Journal of Clinical Pharmacology, 2017 | 89 | 2017 |
| Safety, efficacy and pharmacokinetics of linezolid for treatment of resistant Gram-positive infections in cancer patients with neutropenia PF Smith, MC Birmingham, GA Noskin, AK Meagher, A Forrest, ... Annals of Oncology 14 (5), 795-801, 2003 | 89 | 2003 |
| Pharmacokinetics and pharmacodynamics of aztreonam and tobramycin in hospitalized patients PF Smith, CH Ballow, BM Booker, A Forrest, JJ Schentag Clinical therapeutics 23 (8), 1231-1244, 2001 | 80 | 2001 |
| Application of an in vitro infection model and simulation for reevaluation of fluoroquinolone breakpoints for Salmonella enterica serotype Typhi BM Booker, PF Smith, A Forrest, J Bullock, P Kelchlin, SM Bhavnani, ... Antimicrobial agents and chemotherapy 49 (5), 1775-1781, 2005 | 69 | 2005 |
| Pharmacokinetics, safety, and CCR2/CCR5 antagonist activity of cenicriviroc in participants with mild or moderate hepatic impairment E Lefebvre, M Gottwald, K Lasseter, W Chang, M Willett, PF Smith, ... Clinical and translational science 9 (3), 139-148, 2016 | 67 | 2016 |
| Pharmacokinetic drug interactions with non-nucleoside reverse transcriptase inhibitors Q Ma, OO Okusanya, PF Smith, R DiCenzo, JC Slish, LM Catanzaro, ... Expert opinion on drug metabolism & toxicology 1 (3), 473-485, 2005 | 67 | 2005 |
| Hepatitis C Viral Kinetics With The Nucleoside Polymerase Inhibitor Mericitabine (rg7128) J Guedj, H Dahari, E Tafoya, PF Smith, AS Perelson Hepatology 54 (4), 399A, 2011 | 65 | 2011 |
| Treatment of chronic hepatitis C patients with the NS3/4A protease inhibitor danoprevir (ITMN-191/RG7227) leads to robust reductions in viral RNA: a phase 1b multiple ascending … N Forestier, D Larrey, D Guyader, P Marcellin, R Rouzier, A Patat, P Smith, ... Journal of hepatology 54 (6), 1130-1136, 2011 | 65 | 2011 |
